ADCY8 | Adenylate cyclase 8 (brain) | Enzymes Predicted membrane proteins
| | | | | Group enriched |
ADD2 | Adducin 2 (beta) | Cytoskeleton related proteins
| | | | | Group enriched |
ADGB | Androglobin | Enzymes
| | | | | Group enriched |
ADH1A | Alcohol dehydrogenase 1A (class I), alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
ADH1B | Alcohol dehydrogenase 1B (class I), beta polypeptide | Enzymes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
ADH4 | Alcohol dehydrogenase 4 (class II), pi polypeptide | Enzymes Plasma proteins
| | | | | Tissue enriched |
ADH7 | Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide | Enzymes
| | | | | Tissue enriched |
ADIPOQ | Adiponectin, C1Q and collagen domain containing | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
ADIRF | Adipogenesis regulatory factor | Plasma proteins
| | | | | Tissue enhanced |
ADPRHL1 | ADP-ribosylhydrolase like 1 | | | | | | Group enriched |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AFAP1L2 | Actin filament associated protein 1-like 2 | | | | | | Tissue enhanced |
AFP | Alpha-fetoprotein | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
AGAP2 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 | | | | | | Tissue enhanced |
AGFG2 | ArfGAP with FG repeats 2 | | | | | | Tissue enriched |
AGL | Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins
| | | | | Tissue enriched |
AGMAT | Agmatine ureohydrolase (agmatinase) | Enzymes Mitochondrial proteins
| | | | | Tissue enhanced |
AGR2 | Anterior gradient 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
AGR3 | Anterior gradient 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
AGXT | Alanine-glyoxylate aminotransferase | Disease related genes Enzymes Mitochondrial proteins Plasma proteins Potential drug targets
| | | | | Tissue enriched |
AHNAK2 | AHNAK nucleoprotein 2 | Cancer-related genes
| | | | | Tissue enriched |
AHSG | Alpha-2-HS-glycoprotein | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
AHSP | Alpha hemoglobin stabilizing protein | Plasma proteins
| | | | | Tissue enriched |
AIF1L | Allograft inflammatory factor 1-like | | | | | | Tissue enhanced |
AIM1L | Absent in melanoma 1-like | | | | | | Tissue enhanced |
AK4 | Adenylate kinase 4 | Enzymes Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AK5 | Adenylate kinase 5 | Enzymes
| | | | | Tissue enriched |
AK7 | Adenylate kinase 7 | Enzymes
| | | | | Tissue enhanced |
AKAP14 | A kinase (PRKA) anchor protein 14 | | | | | | Group enriched |
AKAP3 | A kinase (PRKA) anchor protein 3 | | | | | | Tissue enriched |
AKAP4 | A kinase (PRKA) anchor protein 4 | Cytoskeleton related proteins
| | | | | Tissue enriched |
AKAP5 | A kinase (PRKA) anchor protein 5 | Plasma proteins
| | | | | Tissue enhanced |
AKAP6 | A kinase (PRKA) anchor protein 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
AKNAD1 | AKNA domain containing 1 | | | | | | Tissue enhanced |
AKR1B1 | Aldo-keto reductase family 1, member B1 (aldose reductase) | Cancer-related genes Enzymes Plasma proteins
| | | | | Tissue enriched |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | | | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | | | | Tissue enhanced |
AKR1C2 | Aldo-keto reductase family 1, member C2 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
AKR1D1 | Aldo-keto reductase family 1, member D1 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enriched |
ALB | Albumin | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
ALDH1A3 | Aldehyde dehydrogenase 1 family, member A3 | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
ALDH1L1 | Aldehyde dehydrogenase 1 family, member L1 | Enzymes Plasma proteins
| | | | | Tissue enhanced |
ALDH1L2 | Aldehyde dehydrogenase 1 family, member L2 | Enzymes
| | | | | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | | | Tissue enhanced |
ALDH6A1 | Aldehyde dehydrogenase 6 family, member A1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted membrane proteins
| | | | | Group enriched |
ALDH8A1 | Aldehyde dehydrogenase 8 family, member A1 | | | | | | Group enriched |
ALDOB | Aldolase B, fructose-bisphosphate | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Group enriched |
ALLC | Allantoicase | Enzymes
| | | | | Tissue enriched |
ALOX12 | Arachidonate 12-lipoxygenase | Disease related genes Enzymes Potential drug targets
| | | | | Group enriched |
ALOX5 | Arachidonate 5-lipoxygenase | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |